Abstract
Objective
To evaluate bone mineral metabolism in HIV infected and asymptomatic patients receiving highly active antiretroviral therapy (HAART) containing protease inhibitors (PI) and naïve patients.
Methods
We studied 30 asymptomatic HIV infected male patients, 13 in the naive group and 17 in the IP group, both without differences in demographics characteristics. We excluded women and patients with any known factor associated to osteopenia. We did a nutritional questionnaire, a DEXA scan in lumbar spine and femur, a study of CD4 lymphocytes, viral load and an analysis of bone formation and resorption markers in all patients. We compared vitamin D and PTH levels with a control group of healthy male volunteers age-pareated. For the statistical analysis we used the SPSS program.
Results
Osteopenia was present in 17/30 (57%), 8/13 (61.5%) in the naïve group and 9/17 (53%) in the PI group (not significant differences). We found a vitamin D deficiency in 86% of patients, with mean serum levels that was found to be significantly lower than those from a healthy control group (p=0.04). Testosterone level was significantly related to bone mineral density in lumbar spine (p≤0.05).
Conclusions
HIV may be an individual risk factor in bone disorders, requiring calcium and vitamin D supplementation.
This is a preview of subscription content, log in via an institution to check access.
References
Kuhne C, Heufelder A, Hofbauer L (2001) Bone and mineral metabolism in human immunodeficiency virus infection. J Bone Miner Res 16:2–9
Carr A, Samaras K, Chisholm DJ, Cooper DA (1998) Abnormal fat distribution and use of protease inhibitors. Lancet 351:1736
Nolan D, Upton R, McKinnon E, John M, James I, Adler B et al (2001) Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 15:1275–1280
Tebas P, Powderly GW, Claxton S, Marin D, Tantisiriwat W, Teitelbaum LS et al (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14:F63–F67
Bruera D, David DO, Bergoglio LM, Zumudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17(13):1917–1923
Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski K, Dusso A (2003) HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 17:513–520
Haug C, Aukrust P, Haug E, Morkrid L, Muller F, Froland S (1998) Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 83(11):3832–3838
McKenna MJ (1992) Differences in vitamin D status between countries in young adults and the elderly. Am J Med 93:69–77
Aguado P, Garcés MV, Gonzalez Casaus ML, del Campo MT, Rich J, Torrijos A et al (2000) High prevalence of vitamin D deficiency in postmenopausal women at a rheumatology office in Madrid. Evaluation of 2 vitamin D prescription regimens. Med Clin (Barc) 114(9):326–330
Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D (2001) A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 86(3):1212–1221
Bandeira F, Caldas G, Freese E, Griz L, Faria M, Bandeira C (2002) Relationship between serum vitamin D status and clinical manifestations of primary hyperparathyroidism. Endocr Pract 8(4):266–270
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
García Aparicio, A.M., Muñoz Fernández, S., González, J. et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol 25, 537–539 (2006). https://doi.org/10.1007/s10067-005-0028-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-005-0028-x